[Rescue therapy after Helicobacter pylori eradication failure]

Area of Science:

• Gastroenterology
• Infectious Diseases
• Pharmacology

Background:

• First-line Helicobacter pylori eradication therapies fail in at least 20% of patients.
• Current strategies often focus on the first attempt, neglecting planned sequential treatment.
• Antibiotic resistance and suboptimal drug regimens contribute to eradication failures.

Purpose of the Study:

• To emphasize the importance of planning sequential eradication therapies from the outset.
• To guide the selection of effective rescue therapies based on previous treatments.
• To review current and emerging treatment options for H. pylori eradication.

Main Methods:

• Review of current clinical practices and treatment guidelines for H. pylori eradication.
• Analysis of the efficacy of different rescue therapy regimens, including quadruple therapy and levofloxacin-based regimens.
• Discussion of the role of bacterial culture and antibiotic sensitivity testing in managing treatment failures.

Main Results:

• Quadruple therapy (PPI-bismuth-tetracycline-metronidazole) is a common rescue option after clarithromycin-based regimen failure.
• Levofloxacin-based triple therapy demonstrates comparable or superior efficacy to quadruple therapy, with better tolerability.
• Rifabutin-based therapies show promise for patients with multiple eradication failures or antibiotic resistance.

Conclusions:

• Sequential treatment planning is essential for achieving high H. pylori eradication rates.
• Levofloxacin and rifabutin represent valuable options for rescue therapy, particularly in cases of prior treatment failure or resistance.
• Bacterial culture is generally not required after a single eradication failure but may be useful after multiple treatment failures.